sb 203580 has been researched along with Lymphoma, B-Cell in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonavida, B; Franco-Cea, LA; Huerta-Yepez, S; Mayani, H; Morrison, SL; Vega, GG; Vega, MI | 1 |
| Abbott, RT; Bohling, SD; Buckstein, R; Coupland, RW; Dube, ID; Elenitoba-Johnson, KS; Jenson, SD; Lim, MS; Lin, Z; Palais, RA; Perez-Ordonez, B; Perkins, SL; Shami, PJ; Tripp, S; Wang, LY | 1 |
| Bonavida, B; Garban, H; Huerta-Yepez, S; Jazirehi, AR; Vega, MI | 1 |
| Clark, EA; Craxton, A; Graves, JD; Krebs, EG; Saklatvala, J; Shu, G | 1 |
| Bergeron, DM; Chiles, TC; Swart, JM | 1 |
| Furuhata, M; Mizuguchi, J; Suzuki, J; Takada, E; Toyota, H | 1 |
6 other study(ies) available for sb 203580 and Lymphoma, B-Cell
| Article | Year |
|---|---|
Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.
Topics: Animals; Antigens, CD20; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imidazoles; Interferon-alpha; Lymphoma, B-Cell; Mice; Oncogene Proteins, Fusion; p38 Mitogen-Activated Protein Kinases; Pyridines; Rituximab | 2015 |
Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.
Topics: Apoptosis; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Enzyme Inhibitors; Gene Expression Profiling; Humans; Imidazoles; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Oligonucleotide Array Sequence Analysis; p38 Mitogen-Activated Protein Kinases; Pyridines; Receptors, Cytokine; Receptors, Growth Factor; Translocation, Genetic; Tumor Cells, Cultured | 2003 |
Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; fas Receptor; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lymphoma, AIDS-Related; Lymphoma, B-Cell; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Pyridines; Rituximab; Transcription, Genetic | 2005 |
p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes.
Topics: Animals; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Apoptosis; B-Lymphocytes; Calcium-Calmodulin-Dependent Protein Kinases; CD40 Antigens; Cell Division; Enzyme Activation; fas Receptor; Gene Expression Regulation; HLA-DR3 Antigen; Humans; Imidazoles; Immunoglobulin M; Inhibitor of Apoptosis Proteins; Intercellular Adhesion Molecule-1; Intracellular Signaling Peptides and Proteins; Lymphocyte Activation; Lymphoma, B-Cell; Mice; Mitogen-Activated Protein Kinases; Neoplasm Proteins; NF-kappa B; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Palatine Tonsil; Protein Binding; Protein Biosynthesis; Protein Serine-Threonine Kinases; Proteins; Pyridines; Receptors, Antigen, B-Cell; Receptors, Tumor Necrosis Factor; TNF Receptor-Associated Factor 1; TNF Receptor-Associated Factor 4; Tumor Cells, Cultured; Tumor Necrosis Factor Receptor-Associated Peptides and Proteins; Viral Proteins | 1998 |
Identification of a membrane Ig-induced p38 mitogen-activated protein kinase module that regulates cAMP response element binding protein phosphorylation and transcriptional activation in CH31 B cell lymphomas.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Differentiation; Cyclic AMP Response Element-Binding Protein; Enzyme Activation; Enzyme Induction; Enzyme Inhibitors; Imidazoles; Intracellular Signaling Peptides and Proteins; Lymphoma, B-Cell; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-jun; Pyridines; Receptors, Antigen, B-Cell; RNA, Messenger; Serine; Transcriptional Activation; Tumor Cells, Cultured | 2000 |
Requirement of c-Jun N terminal kinase and P38 mitogen-activated protein kinase for anti-IgM-induced reduction in mitochondrial membrane potential in CH31 B lymphoma cells.
Topics: Amino Acid Chloromethyl Ketones; B-Lymphocytes; Caspase Inhibitors; Cysteine Proteinase Inhibitors; Enzyme Inhibitors; Imidazoles; Immunoglobulin M; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Lymphoma, B-Cell; Membrane Potentials; Mitochondria; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Tumor Cells, Cultured | 2002 |